Melanotan I vs Melanotan II: Head-to-Head Comparison

The melanocortin receptor system consists of five receptor subtypes (MC1–MC5), each mediating different physiological effects. The critical difference between Melanotan I and II lies in which of these receptors each peptide activates.

Melanotan I: Selective MC1 Receptor Agonism

Melanotan I (afamelanotide, also designated [Nle4-D-Phe7]-alpha-MSH) is a linear peptide analog of alpha-MSH that was engineered for enhanced potency and selectivity at the MC1 receptor. The MC1 receptor is expressed primarily on melanocytes—the skin cells responsible for melanin production.^[1]

When Melanotan I binds MC1, it triggers a signaling cascade via cAMP upregulation that shifts melanogenesis toward eumelanin production. Eumelanin is the brown-black pigment that provides genuine photoprotection against UV radiation, as opposed to pheomelanin (red-yellow pigment), which can actually generate free radicals under UV exposure. This eumelanin-preferential pathway is why Melanotan I produces a more natural-appearing tan and provides measurable photoprotection.^[1]

Because Melanotan I has minimal affinity for MC3, MC4, and MC5 receptors, it produces few effects beyond skin pigmentation. This selectivity is what enabled its development as a pharmaceutical product (Scenesse) for patients with erythropoietic protoporphyria (EPP), a condition causing extreme UV photosensitivity.

Melanotan II: Broad Melanocortin Agonism

Melanotan II is a cyclic heptapeptide analog of alpha-MSH that was developed alongside Melanotan I at the University of Arizona. Its cyclic lactam bridge structure gives it greater metabolic stability but also broader receptor affinity across the melanocortin system.^[2]

Melanotan II activates multiple melanocortin receptors with significant potency:

• MC1 receptor: Melanin production and skin darkening (same as Melanotan I)
• MC3 receptor: Energy homeostasis, cardiovascular function, and inflammatory modulation
• MC4 receptor: Sexual arousal, appetite suppression, and energy balance regulation
• MC5 receptor: Exocrine gland function, including sebaceous gland activity

This broad activation explains why Melanotan II produces a range of effects beyond tanning, including spontaneous erections, increased sexual arousal in both sexes, appetite suppression, and nausea. The MC4-mediated sexual effects were significant enough that they led to the development of PT-141 (bremelanotide)—a modified version of Melanotan II that was eventually FDA-approved specifically for hypoactive sexual desire disorder in women.^[3]

Melanotan I has a substantially stronger clinical evidence base than Melanotan II, having progressed through formal clinical trials to FDA approval, while Melanotan II remains a research compound.

Melanotan I (Afamelanotide) Clinical Data

Afamelanotide has been evaluated in multiple Phase II and Phase III clinical trials conducted by Clinuvel Pharmaceuticals:

• Erythropoietic protoporphyria (EPP): In the pivotal Phase III PASS study, afamelanotide significantly increased pain-free time in sunlight for EPP patients, with a median increase of 69.4 hours over 180 days compared to placebo. This led to FDA approval of Scenesse in October 2019.^[1]
• Photoprotection in healthy volunteers: Clinical trials demonstrated that afamelanotide produces measurable skin darkening within 48 hours of implantation and sustained pigmentation for 40–60 days. Skin biopsies confirmed increased eumelanin density in the epidermis.
• Vitiligo: Phase II trials exploring afamelanotide combined with narrowband UVB phototherapy for vitiligo showed enhanced and accelerated repigmentation compared to UVB alone, particularly in facial and upper extremity lesions.
• Polymorphous light eruption: Studies demonstrated reduced severity and frequency of sun-triggered skin eruptions in treated subjects.
• Safety record: Across all clinical trials, afamelanotide demonstrated a favorable safety profile. The most common adverse effects were nausea (16%), headache (12%), nasopharyngitis (8%), and injection site reactions. Importantly, dermatological surveillance showed no increase in melanocytic nevi (moles) or melanoma risk over multi-year follow-up periods.^[1]

Melanotan II Research Data

Melanotan II has been studied in several small clinical trials but has not advanced to Phase III:

• Tanning efficacy: A Phase I study by Dorr et al. demonstrated that 10 days of low-dose Melanotan II (0.01–0.025 mg/kg) produced significant skin darkening without UV exposure, confirming its melanogenic effect in humans.^[2]
• Sexual function: Studies in men with erectile dysfunction showed that Melanotan II produced erections in a majority of subjects, an effect mediated through MC4 receptor activation. This finding spawned the development of PT-141 as a targeted pharmaceutical.^[3]
• Appetite effects: MC4 receptor activation by Melanotan II has been shown to reduce food intake in both animal and human studies, though this effect is considered a side effect rather than a primary research endpoint.
• Safety concerns: Melanotan II's side-effect profile includes significant nausea (especially at initial doses), facial flushing, fatigue, and in rare cases, changes to existing moles. Case reports have documented atypical nevi and melanoma in Melanotan II users, though a causal relationship has not been established. The non-selective melanocortin activation introduces theoretical risks that have prevented regulatory advancement.^[4]

The safety profiles of these two peptides differ significantly, primarily because of Melanotan II's non-selective melanocortin activation.

Melanotan I Safety Profile

• Nausea: Mild, dose-dependent nausea is the most commonly reported side effect, occurring in approximately 16% of clinical trial subjects. It is typically transient and diminishes with continued use.
• Headache: Reported in approximately 12% of subjects in clinical trials.
• Skin changes: The intended effect—increased pigmentation—occurs predictably. Multi-year surveillance has shown no statistically significant increase in new moles or melanoma risk in treated populations.^[1]
• Pigmentation quality: Because Melanotan I preferentially increases eumelanin, the resulting pigmentation provides genuine UV protection and appears more natural than Melanotan II-induced tanning.

Melanotan II Safety Profile

• Nausea: More pronounced than Melanotan I, particularly during the initial loading phase. Many users report significant nausea that can last 30–60 minutes post-injection.
• Facial flushing: Commonly reported, likely mediated through MC3 and MC4 receptor effects on cardiovascular function.
• Sexual effects: Spontaneous erections in males and heightened sexual arousal in both sexes are frequently reported. While some users consider this a benefit, it is an unpredictable and uncontrollable off-target effect.^[3]
• Appetite suppression: MC4-mediated reduction in appetite can be significant and may be unwanted in some contexts.
• Mole changes: The most clinically concerning side effect. Multiple case reports describe darkening and morphological changes in existing nevi, and rare cases of melanoma have been reported in Melanotan II users. While causation is unproven, the association has raised regulatory red flags.^[4]
• Cardiovascular effects: MC3 receptor activation can transiently affect blood pressure and heart rate.

Safety Summary

Melanotan I has a substantially superior safety profile, supported by clinical trial data and multi-year post-market surveillance. Its MC1 selectivity eliminates the sexual, appetite, and cardiovascular effects associated with Melanotan II, and its eumelanin-specific tanning may actually reduce UV-related skin damage. Melanotan II's broad melanocortin activation introduces multiple unpredictable effects and unresolved concerns about mole changes that have prevented its regulatory approval.

Despite sharing a common origin and both producing skin pigmentation, Melanotan I and II serve different niches in research and clinical practice.

Melanotan I Is Better Suited For:

• Photoprotection research: Melanotan I (afamelanotide) is the only melanocortin peptide with FDA approval for a photoprotection indication. Its eumelanin-specific mechanism provides genuine UV protection, making it relevant for research in photosensitivity disorders, UV damage prevention, and skin cancer chemoprevention.
• Clinical applications: As an FDA-approved drug (Scenesse), afamelanotide is the only option with established clinical dosing, safety monitoring protocols, and regulatory oversight.
• Research requiring clean skin pigmentation data: Because Melanotan I does not produce sexual, appetite, or cardiovascular effects, it isolates pigmentation as the sole variable under study.
• Vitiligo and pigmentation disorders: Clinical trials have demonstrated potential for repigmentation of depigmented patches, particularly when combined with phototherapy.

Melanotan II Is More Commonly Used For:

• Cosmetic tanning research: Melanotan II remains widely used in the research peptide community for cosmetic tanning, despite its unregulated status. Its broader melanocortin activation produces faster and more dramatic skin darkening than Melanotan I.
• Sexual function research: Melanotan II's MC4-mediated sexual effects are well-documented, and it was the parent compound from which PT-141 (bremelanotide) was derived. Researchers interested in melanocortin-mediated sexual function may study Melanotan II as a multi-target reference compound.
• Appetite and energy metabolism: The MC3/MC4 appetite suppression effects make Melanotan II of interest in obesity and energy homeostasis research, though more targeted compounds have largely superseded it for this purpose.

It is important to note that Melanotan II is sold exclusively as a research compound and has no regulatory approval for any indication. Users who self-administer Melanotan II for cosmetic tanning do so outside of any clinical oversight, which introduces unmonitored risks including potential mole changes and unpredictable systemic effects.